Nu Skin Enterprises, Inc. (NUS) 10-Year Financial Performance & Capital Metrics

NUS • • Industrial / General

Consumer DefensiveHousehold ProductsHealth & Wellness ProductsNutritional Supplements

AboutNu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.Show more

Revenue $1.73B -12.0%
EBITDA -$82M -169.6%
Net Income -$147M -1805.6%
EPS (Diluted) -2.95 -1835.3%
Gross Margin 68.23% -1.0%
EBITDA Margin -4.72% -179.1%
Operating Margin -8.75% -457.0%
Net Margin -8.46% -2038.9%
ROE -19.9% -2090.2%
ROIC -10.75% -445.3%
Debt/Equity 0.73 -0.6%
Interest Coverage -5.74 -404.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Healthy dividend yield of 2.1%
✓Trading at only 0.9x book value
✓Efficient asset utilization: 1.2x turnover

✗Weaknesses

✗Sales declining 6.5% over 5 years
✗Thin 5Y average net margin of 1.9%

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-3.87%

5Y-6.47%

3Y-13.71%

TTM-12.1%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM206.2%

EPS CAGR

10Y-

5Y-

3Y-

TTM205.27%

ROCE

10Y Avg14.21%

5Y Avg6.93%

3Y Avg-0.12%

Latest-11.44%

Peer Comparison

Nutritional Supplements

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SGISomnigroup International Inc	19.52B	92.99	43.05	0.11%	4.62%	10.53%	2.92%	7.86
KVUEKenvue Inc.	33.07B	17.26	31.96	0.07%	9.55%	13.48%	4.04%	0.90
MTEXMannatech, Incorporated	17.36M	9.13	6.92	-10.68%	-1.5%	-23.83%	11.32%	0.78
NUSNu Skin Enterprises, Inc.	552.83M	11.34	-3.84	-12.04%	7.02%	13.7%	12.69%	0.73

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	2.25B	2.21B	2.28B	2.68B	2.42B	2.58B	2.7B	2.23B	1.97B	1.73B
Revenue Growth %	-0.13%	-0.02%	0.03%	0.18%	-0.1%	0.07%	0.04%	-0.17%	-0.12%	-0.12%
Cost of Goods Sold+	489.51M	500.46M	502.08M	634.14M	581.42M	658.03M	675.22M	630.91M	611.85M	550.23M
COGS % of Revenue	0.22%	0.23%	0.22%	0.24%	0.24%	0.25%	0.25%	0.28%	0.31%	0.32%
Gross Profit+	1.76B	1.71B	1.78B	2.04B	1.84B	1.92B	2.02B	1.59B	1.36B	1.18B
Gross Margin %	0.78%	0.77%	0.78%	0.76%	0.76%	0.75%	0.75%	0.72%	0.69%	0.68%
Gross Profit Growth %	-0.16%	-0.03%	0.04%	0.15%	-0.1%	0.05%	0.05%	-0.21%	-0.15%	-0.13%
Operating Expenses+	1.51B	1.48B	1.5B	1.73B	1.57B	1.67B	1.79B	1.48B	1.31B	1.33B
OpEx % of Revenue	0.67%	0.67%	0.66%	0.65%	0.65%	0.65%	0.66%	0.67%	0.66%	0.77%
Selling, General & Admin	1.51B	1.48B	1.5B	1.73B	1.57B	1.67B	1.73B	1.44B	1.29B	1.13B
SG&A % of Revenue	0.67%	0.67%	0.66%	0.65%	0.65%	0.65%	0.64%	0.64%	0.65%	0.65%
Research & Development	20.1M	24.3M	22M	23M	0	23.3M	27.2M	0	22.6M	13M
R&D % of Revenue	0.01%	0.01%	0.01%	0.01%	-	0.01%	0.01%	-	0.01%	0.01%
Other Operating Expenses	-32.74M	-18.27M	-8.92M	-21.19M	0	-23.3M	24.67M	48.49M	-2.81M	189.36M
Operating Income+	244.7M	231.1M	274.48M	240.86M	267.43M	257.56M	233.99M	110.85M	48.27M	-151.59M
Operating Margin %	0.11%	0.1%	0.12%	0.09%	0.11%	0.1%	0.09%	0.05%	0.02%	-0.09%
Operating Income Growth %	-0.31%	-0.06%	0.19%	-0.12%	0.11%	-0.04%	-0.09%	-0.53%	-0.56%	-4.14%
EBITDA+	316.07M	303.5M	346.05M	323.86M	344.08M	331.56M	359.02M	183.35M	117.49M	-81.78M
EBITDA Margin %	0.14%	0.14%	0.15%	0.12%	0.14%	0.13%	0.13%	0.08%	0.06%	-0.05%
EBITDA Growth %	-0.22%	-0.04%	0.14%	-0.06%	0.06%	-0.04%	0.08%	-0.49%	-0.36%	-1.7%
D&A (Non-Cash Add-back)	71.36M	72.4M	71.56M	83M	76.65M	73.99M	125.02M	72.51M	69.22M	69.81M
EBIT	244.7M	231.1M	274.48M	311.55M	267.43M	257.56M	243.46M	102.46M	133.76M	-148.64M
Net Interest Income+	0	0	0	0	0	24K	157K	-11.49M	-25.56M	-26.41M
Interest Income	0	0	0	0	19.2M	13.12M	11.16M	10.38M	0	0
Interest Expense	0	0	0	0	19.2M	13.1M	11M	21.88M	25.56M	26.41M
Other Income/Expense	-32.74M	-18.27M	-8.92M	-21.19M	-12.25M	-1.33M	-1.53M	-21.88M	-21.69M	-23.47M
Pretax Income+	211.96M	212.84M	265.57M	219.67M	255.17M	256.23M	232.46M	88.97M	26.58M	-175.05M
Pretax Margin %	0.09%	0.1%	0.12%	0.08%	0.11%	0.1%	0.09%	0.04%	0.01%	-0.1%
Income Tax+	78.91M	69.75M	136.13M	97.78M	81.62M	64.88M	85.19M	-15.81M	17.98M	-28.46M
Effective Tax Rate %	0.63%	0.67%	0.49%	0.55%	0.68%	0.75%	0.63%	1.18%	0.32%	0.84%
Net Income+	133.05M	143.09M	129.44M	121.89M	173.55M	191.35M	147.27M	104.78M	8.6M	-146.59M
Net Margin %	0.06%	0.06%	0.06%	0.05%	0.07%	0.07%	0.05%	0.05%	0%	-0.08%
Net Income Growth %	-0.3%	0.08%	-0.1%	-0.06%	0.42%	0.1%	-0.23%	-0.29%	-0.92%	-18.06%
Net Income (Continuing)	133.05M	143.09M	129.44M	121.89M	173.55M	191.35M	147.27M	104.78M	8.6M	-146.59M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	2.25	2.55	2.36	2.16	3.10	3.63	2.86	2.07	0.17	-2.95
EPS Growth %	-0.28%	0.13%	-0.07%	-0.08%	0.44%	0.17%	-0.21%	-0.28%	-0.92%	-18.35%
EPS (Basic)	2.29	2.58	2.45	2.21	3.13	3.66	2.93	2.10	0.17	-2.95
Diluted Shares Outstanding	59.06M	56.1M	54.85M	56.48M	55.93M	52.77M	51.43M	50.52M	49.86M	49.66M
Basic Shares Outstanding	58M	55.41M	52.81M	55.17M	55.52M	52.3M	50.19M	50M	49.71M	49.66M
Dividend Payout Ratio	0.61%	0.55%	0.59%	0.66%	0.47%	0.41%	0.52%	0.74%	9.03%	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	706.39M	714.34M	777.79M	799.24M	740.17M	903.2M	872.95M	759.87M	701.87M	538.6M
Cash & Short-Term Investments	303.73M	368.13M	438.25M	398.26M	344.04M	423.9M	354.81M	278.51M	267.82M	197.99M
Cash Only	289.35M	357.25M	426.4M	386.91M	335.63M	402.68M	339.59M	264.73M	256.06M	186.88M
Short-Term Investments	14.37M	10.88M	11.85M	11.35M	8.41M	21.22M	15.22M	13.78M	11.76M	11.11M
Accounts Receivable	35.46M	31.2M	33.2M	53.28M	50.38M	63.37M	41.3M	47.36M	72.88M	50.78M
Days Sales Outstanding	5.76	5.16	5.32	7.26	7.6	8.96	5.59	7.77	13.51	10.7
Inventory	265.26M	249.94M	253.45M	295.82M	275.89M	314.37M	399.93M	346.18M	279.98M	190.24M
Days Inventory Outstanding	197.79	182.29	184.26	170.27	173.2	174.37	216.19	200.28	167.02	126.2
Other Current Assets	29.23M	24.04M	18.4M	22.51M	24.51M	25.27M	32.43M	39.33M	37.1M	51.39M
Total Non-Current Assets+	799.45M	759.71M	812.08M	895.21M	1.03B	1.05B	1.03B	1.06B	1.1B	930.32M
Property, Plant & Equipment	454.54M	444.73M	464.59M	464.54M	644.82M	653.45M	598.25M	571.67M	523.07M	466.91M
Fixed Asset Turnover	4.94x	4.96x	4.91x	5.77x	3.75x	3.95x	4.51x	3.89x	3.76x	3.71x
Goodwill	112.45M	114.95M	114.95M	196.57M	196.57M	202.98M	206.43M	206.43M	230.77M	83.63M
Intangible Assets	67.01M	63.55M	67.65M	89.99M	80.32M	89.53M	76.99M	66.7M	105.31M	74.28M
Long-Term Investments	-40.37M	-35.75M	-33.78M	-37.33M	0	11.34M	35.87M	39.49M	40.11M	39.59M
Other Non-Current Assets	165.46M	136.47M	164.9M	144.11M	76.34M	61.16M	89.51M	87.03M	99.81M	91.67M
Total Assets+	1.51B	1.47B	1.59B	1.69B	1.77B	1.96B	1.91B	1.82B	1.81B	1.47B
Asset Turnover	1.49x	1.50x	1.43x	1.58x	1.37x	1.32x	1.41x	1.22x	1.09x	1.18x
Asset Growth %	-0.07%	-0.02%	0.08%	0.07%	0.04%	0.11%	-0.03%	-0.04%	-0.01%	-0.19%
Total Current Liabilities+	407.6M	399.01M	447.37M	439.65M	356.76M	542.86M	529.69M	359.24M	328.87M	296.61M
Accounts Payable	28.83M	41.26M	50.34M	47.62M	38.98M	66.17M	49.99M	53.96M	43.51M	34.88M
Days Payables Outstanding	21.5	30.09	36.6	27.41	24.47	36.71	27.02	31.22	25.95	23.14
Short-Term Debt	67.85M	82.73M	77.84M	69.45M	27.5M	30M	107.5M	25M	25M	30M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	279.88M	109.96M	103.73M	99.63M	3.9M	137.97M	3.51M	3.36M	89.64M	23.89M
Current Ratio	1.73x	1.79x	1.74x	1.82x	2.07x	1.66x	1.65x	2.12x	2.13x	1.82x
Quick Ratio	1.08x	1.16x	1.17x	1.15x	1.30x	1.08x	0.89x	1.15x	1.28x	1.17x
Cash Conversion Cycle	182.05	157.35	152.98	150.12	156.32	146.63	194.76	176.82	154.58	113.76
Total Non-Current Liabilities+	272.63M	410.96M	437.91M	472.92M	536.96M	519.95M	464.01M	564.43M	655.62M	520.85M
Long-Term Debt	181.75M	334.17M	310.79M	361.01M	334.46M	305.39M	268.78M	377.47M	478.04M	363.61M
Capital Lease Obligations	0	0	0	9.33M	105.7M	120M	94.08M	88.68M	80.39M	66.69M
Deferred Tax Liabilities	16.18M	643K	36.72M	32.62M	27.86M	23.36M	24.16M	35.97M	522K	39.87M
Other Non-Current Liabilities	90.88M	76.8M	127.12M	102.58M	68.93M	71.2M	77M	62.31M	96.67M	50.68M
Total Liabilities	680.22M	809.98M	885.28M	912.58M	893.72M	1.06B	993.71M	923.67M	984.5M	817.46M
Total Debt+	249.59M	416.89M	388.63M	430.46M	507.01M	500.38M	503.79M	520.52M	607.33M	478.23M
Net Debt	-39.76M	59.65M	-37.77M	43.55M	171.38M	97.69M	164.19M	255.8M	351.27M	291.34M
Debt / Equity	0.30x	0.63x	0.55x	0.55x	0.58x	0.56x	0.55x	0.58x	0.74x	0.73x
Debt / EBITDA	0.79x	1.37x	1.12x	1.33x	1.47x	1.51x	1.40x	2.84x	5.17x	-
Net Debt / EBITDA	-0.13x	0.20x	-0.11x	0.13x	0.50x	0.29x	0.46x	1.40x	2.99x	-
Interest Coverage	-	-	-	-	13.93x	19.66x	21.27x	5.07x	1.89x	-5.74x
Total Equity+	825.62M	664.07M	704.6M	781.87M	875.29M	894.27M	912.77M	897.3M	821.97M	651.46M
Equity Growth %	-0.12%	-0.2%	0.06%	0.11%	0.12%	0.02%	0.02%	-0.02%	-0.08%	-0.21%
Book Value per Share	13.98	11.84	12.85	13.84	15.65	16.95	17.75	17.76	16.49	13.12
Total Shareholders' Equity	825.62M	664.07M	704.6M	781.87M	875.29M	894.27M	912.77M	897.3M	821.97M	651.46M
Common Stock	91K	91K	91K	91K	91K	91K	91K	91K	91K	91K
Retained Earnings	1.49B	1.56B	1.61B	1.64B	1.73B	1.84B	1.91B	1.94B	1.87B	1.71B
Treasury Stock	-1.02B	-1.25B	-1.3B	-1.33B	-1.32B	-1.46B	-1.53B	-1.57B	-1.57B	-1.56B
Accumulated OCI	-71.27M	-84.12M	-66.32M	-79.93M	-85.29M	-64.77M	-73.9M	-86.51M	-100.01M	-124.76M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	322.11M	275.26M	302.56M	202.74M	177.93M	379.14M	141.58M	108.06M	118.64M	111.74M
Operating CF Margin %	0.14%	0.12%	0.13%	0.08%	0.07%	0.15%	0.05%	0.05%	0.06%	0.06%
Operating CF Growth %	6.7%	-0.15%	0.1%	-0.33%	-0.12%	1.13%	-0.63%	-0.24%	0.1%	-0.06%
Net Income	133.05M	143.09M	129.44M	121.89M	173.55M	191.35M	147.27M	104.78M	8.6M	-146.59M
Depreciation & Amortization	71.36M	72.4M	71.56M	83M	76.65M	73.99M	76.32M	72.51M	70.92M	69.81M
Stock-Based Compensation	7.4M	8.89M	19.31M	26.61M	9.91M	24.06M	23.19M	12.37M	15.65M	14.82M
Deferred Taxes	17.36M	-17.65M	39.21M	-14.93M	1.97M	-11.91M	5.82M	-51.63M	-18.09M	-55.48M
Other Non-Cash Items	27.23M	40.22M	-4.06M	58.05M	48.29M	49.09M	82.6M	62.71M	123.25M	257.51M
Working Capital Changes	65.7M	28.32M	47.09M	-71.88M	-132.44M	52.56M	-193.62M	-92.67M	-81.68M	-28.34M
Change in Receivables	-2.25M	3.36M	-103K	-10.45M	2.75M	-11.21M	20.22M	-11.45M	-22.68M	-7.76M
Change in Inventory	59.65M	9.8M	7.54M	-33.37M	18.45M	-31.14M	-95.32M	40.31M	-13.22M	30.32M
Change in Payables	-4.3M	13.44M	6.83M	-9.16M	-7.18M	24.84M	-13.28M	9.26M	-10.08M	-7.29M
Cash from Investing+	-60.85M	-57.86M	-91.96M	-108.76M	-71.41M	-79.43M	-88.73M	-67.08M	-134.5M	-37.96M
Capital Expenditures	-56.62M	-50.22M	-60.16M	-70.37M	-66.07M	-63.82M	-68.61M	-59.06M	-58.49M	-41.58M
CapEx % of Revenue	0.03%	0.02%	0.03%	0.03%	0.03%	0.02%	0.03%	0.03%	0.03%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-4.22M	1.05M	-63K	116K	0	0	0	-8.02M	0	0
Cash from Financing+	-235.92M	-134.71M	-159.57M	-116.71M	-154.79M	-245.17M	-104.7M	-99.5M	10.73M	-133.18M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-81.19M	-78.44M	-76.06M	-80.58M	-82.19M	-78.39M	-76.27M	-77.02M	-77.62M	-11.93M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	8.65M	13.36M	24.44M	3.53M	-2.33M	5.76M	13.86M	21.98M	4.56M	-6.3M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	265.49M	225.04M	242.4M	132.37M	111.86M	315.32M	72.97M	49.01M	60.15M	70.16M
FCF Margin %	0.12%	0.1%	0.11%	0.05%	0.05%	0.12%	0.03%	0.02%	0.03%	0.04%
FCF Growth %	2.68%	-0.15%	0.08%	-0.45%	-0.15%	1.82%	-0.77%	-0.33%	0.23%	0.17%
FCF per Share	4.50	4.01	4.42	2.34	2.00	5.98	1.42	0.97	1.21	1.41
FCF Conversion (FCF/Net Income)	2.42x	1.92x	2.34x	1.66x	1.03x	1.98x	0.96x	1.03x	13.80x	-0.76x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	15.05%	19.21%	18.91%	16.4%	20.95%	21.63%	16.3%	11.58%	1%	-19.9%
Return on Invested Capital (ROIC)	21.75%	22.96%	29.61%	24.21%	21.43%	18.95%	16.96%	7.46%	3.11%	-10.75%
Gross Margin	78.22%	77.33%	77.97%	76.33%	75.98%	74.51%	74.95%	71.65%	68.93%	68.23%
Net Margin	5.92%	6.48%	5.68%	4.55%	7.17%	7.41%	5.46%	4.71%	0.44%	-8.46%
Debt / Equity	0.30x	0.63x	0.55x	0.55x	0.58x	0.56x	0.55x	0.58x	0.74x	0.73x
Interest Coverage	-	-	-	-	13.93x	19.66x	21.27x	5.07x	1.89x	-5.74x
FCF Conversion	2.42x	1.92x	2.34x	1.66x	1.03x	1.98x	0.96x	1.03x	13.80x	-0.76x
Revenue Growth	-12.55%	-1.75%	3.23%	17.55%	-9.65%	6.67%	4.41%	-17.44%	-11.53%	-12.04%

Revenue by Segment

	2014	2015	2017	2018	2019	2020	2021	2022	2023	2024
Nu Skin	1.56B	1.36B	1.46B	1.66B	2.3B	2.43B	2.52B	2.07B	1.75B	1.45B
Nu Skin Growth	-	-12.74%	6.81%	13.96%	38.48%	5.80%	3.67%	-17.80%	-15.43%	-17.52%
Manufacturing	-	-	-	-	121.92M	149.34M	172.12M	149.46M	181.4M	201.43M
Manufacturing Growth	-	-	-	-	-	22.49%	15.25%	-13.17%	21.37%	11.04%
Rhyz Other	-	-	-	-	-	-	437K	3.83M	35.21M	85.19M
Rhyz Other Growth	-	-	-	-	-	-	-	776.43%	819.43%	141.92%
Grow Tech	-	-	-	-	137K	903K	-	-	-	-
Grow Tech Growth	-	-	-	-	-	559.12%	-	-	-	-
Pharmanex	1B	877.92M	817.23M	921.33M	-	-	-	-	-	-
Pharmanex Growth	-	-12.23%	-6.91%	12.74%	-	-	-	-	-	-
Other Product Lines	6.62M	5.58M	5.48M	97.94M	-	-	-	-	-	-
Other Product Lines Growth	-	-15.66%	-1.81%	1686.30%	-	-	-	-	-	-

Revenue by Geography

	2014	2015	2017	2018	2019	2020	2021	2022	2023	2024
Americas	-	-	-	-	-	-	547.75M	508.54M	398.22M	322.52M
Americas Growth	-	-	-	-	-	-	-	-7.16%	-21.69%	-19.01%
Southeast Asia/Pacific	-	-	-	-	-	-	336.65M	344.41M	267.21M	244.85M
Southeast Asia/Pacific Growth	-	-	-	-	-	-	-	2.31%	-22.42%	-8.37%
Mainland China	-	-	-	-	-	625.54M	568.77M	360.39M	298.08M	235.24M
Mainland China Growth	-	-	-	-	-	-	-9.07%	-36.64%	-17.29%	-21.08%
Japan	-	-	-	-	-	273.68M	266.22M	224.9M	207.83M	181.56M
Japan Growth	-	-	-	-	-	-	-2.73%	-15.52%	-7.59%	-12.64%
Europe and Africa	-	-	-	-	-	-	-	-	192.35M	164.16M
Europe and Africa Growth	-	-	-	-	-	-	-	-	-	-14.65%
EMEA	-	-	-	-	-	230.25M	283.2M	204.28M	-	-
EMEA Growth	-	-	-	-	-	-	23.00%	-27.87%	-	-
Americas/ Pacific	-	-	-	-	-	511.94M	-	-	-	-
Americas/ Pacific Growth	-	-	-	-	-	-	-	-	-	-
Southeast Asia	-	-	-	-	-	302.71M	-	-	-	-
Southeast Asia Growth	-	-	-	-	-	-	-	-	-	-
Mainland China	-	-	716.99M	886.47M	722.53M	-	-	-	-	-
Mainland China Growth	-	-	-	23.64%	-18.49%	-	-	-	-	-
Americas/Pacific	-	-	-	385.03M	349.08M	-	-	-	-	-
Americas/Pacific Growth	-	-	-	-	-9.34%	-	-	-	-	-
South Korea	-	-	361.69M	373.36M	329.98M	-	-	-	-	-
South Korea Growth	-	-	-	3.23%	-11.62%	-	-	-	-	-
Southeast Asia	-	-	-	316.89M	301.62M	-	-	-	-	-
Southeast Asia Growth	-	-	-	-	-4.82%	-	-	-	-	-
Japan	-	-	256.08M	254.94M	260.04M	-	-	-	-	-
Japan Growth	-	-	-	-0.45%	2.00%	-	-	-	-	-
EMEA	180.57M	-	160.28M	182.39M	167.16M	-	-	-	-	-
EMEA Growth	-	-	-	13.80%	-8.35%	-	-	-	-	-
Hong Kong/Taiwan	-	-	166.7M	185.89M	166.34M	-	-	-	-	-
Hong Kong/Taiwan Growth	-	-	-	11.52%	-10.52%	-	-	-	-	-
Other	-	-	-	94.03M	-	-	-	-	-	-
Other Growth	-	-	-	-	-	-	-	-	-	-
Americas	329.03M	329.67M	317.38M	-	-	-	-	-	-	-
Americas Growth	-	0.19%	-3.73%	-	-	-	-	-	-	-
South Asia Pacific	328.39M	321.97M	299.98M	-	-	-	-	-	-	-
South Asia Pacific Growth	-	-1.95%	-6.83%	-	-	-	-	-	-	-
China	948.52M	771.67M	-	-	-	-	-	-	-	-
China Growth	-	-18.65%	-	-	-	-	-	-	-	-
North Asia	782.99M	686.55M	-	-	-	-	-	-	-	-
North Asia Growth	-	-12.32%	-	-	-	-	-	-	-	-
Europe	-	137.19M	-	-	-	-	-	-	-	-
Europe Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Nu Skin Enterprises, Inc. (NUS) reported $1.56B in revenue for fiscal year 2024. This represents a 11% decrease from $1.74B in 2011.

Nu Skin Enterprises, Inc. (NUS) saw revenue decline by 12.0% over the past year.

Yes, Nu Skin Enterprises, Inc. (NUS) is profitable, generating $109.6M in net income for fiscal year 2024 (-8.5% net margin).

Dividend & Returns

Yes, Nu Skin Enterprises, Inc. (NUS) pays a dividend with a yield of 2.12%. This makes it attractive for income-focused investors.

Nu Skin Enterprises, Inc. (NUS) has a return on equity (ROE) of -19.9%. Negative ROE indicates the company is unprofitable.

Nu Skin Enterprises, Inc. (NUS) generated $53.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Nu Skin Enterprises, Inc. (NUS) 10-Year Financial Performance & Capital Metrics

NUS • • Industrial / General

Consumer DefensiveHousehold ProductsHealth & Wellness ProductsNutritional Supplements

Revenue $1.73B -12.0%
EBITDA -$82M -169.6%
Net Income -$147M -1805.6%
EPS (Diluted) -2.95 -1835.3%
Gross Margin 68.23% -1.0%
EBITDA Margin -4.72% -179.1%
Operating Margin -8.75% -457.0%
Net Margin -8.46% -2038.9%
ROE -19.9% -2090.2%
ROIC -10.75% -445.3%
Debt/Equity 0.73 -0.6%
Interest Coverage -5.74 -404.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Healthy dividend yield of 2.1%
✓Trading at only 0.9x book value
✓Efficient asset utilization: 1.2x turnover

✗Weaknesses

✗Sales declining 6.5% over 5 years
✗Thin 5Y average net margin of 1.9%

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-3.87%

5Y-6.47%

3Y-13.71%

TTM-12.1%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM206.2%

EPS CAGR

10Y-

5Y-

3Y-

TTM205.27%

ROCE

10Y Avg14.21%

5Y Avg6.93%

3Y Avg-0.12%

Latest-11.44%

Peer Comparison

Nutritional Supplements

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
SGISomnigroup International Inc	19.52B	92.99	43.05	0.11%	4.62%	10.53%	2.92%	7.86
KVUEKenvue Inc.	33.07B	17.26	31.96	0.07%	9.55%	13.48%	4.04%	0.90
MTEXMannatech, Incorporated	17.36M	9.13	6.92	-10.68%	-1.5%	-23.83%	11.32%	0.78
NUSNu Skin Enterprises, Inc.	552.83M	11.34	-3.84	-12.04%	7.02%	13.7%	12.69%	0.73

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	2.25B	2.21B	2.28B	2.68B	2.42B	2.58B	2.7B	2.23B	1.97B	1.73B
Revenue Growth %	-0.13%	-0.02%	0.03%	0.18%	-0.1%	0.07%	0.04%	-0.17%	-0.12%	-0.12%
Cost of Goods Sold+	489.51M	500.46M	502.08M	634.14M	581.42M	658.03M	675.22M	630.91M	611.85M	550.23M
COGS % of Revenue	0.22%	0.23%	0.22%	0.24%	0.24%	0.25%	0.25%	0.28%	0.31%	0.32%
Gross Profit+	1.76B	1.71B	1.78B	2.04B	1.84B	1.92B	2.02B	1.59B	1.36B	1.18B
Gross Margin %	0.78%	0.77%	0.78%	0.76%	0.76%	0.75%	0.75%	0.72%	0.69%	0.68%
Gross Profit Growth %	-0.16%	-0.03%	0.04%	0.15%	-0.1%	0.05%	0.05%	-0.21%	-0.15%	-0.13%
Operating Expenses+	1.51B	1.48B	1.5B	1.73B	1.57B	1.67B	1.79B	1.48B	1.31B	1.33B
OpEx % of Revenue	0.67%	0.67%	0.66%	0.65%	0.65%	0.65%	0.66%	0.67%	0.66%	0.77%
Selling, General & Admin	1.51B	1.48B	1.5B	1.73B	1.57B	1.67B	1.73B	1.44B	1.29B	1.13B
SG&A % of Revenue	0.67%	0.67%	0.66%	0.65%	0.65%	0.65%	0.64%	0.64%	0.65%	0.65%
Research & Development	20.1M	24.3M	22M	23M	0	23.3M	27.2M	0	22.6M	13M
R&D % of Revenue	0.01%	0.01%	0.01%	0.01%	-	0.01%	0.01%	-	0.01%	0.01%
Other Operating Expenses	-32.74M	-18.27M	-8.92M	-21.19M	0	-23.3M	24.67M	48.49M	-2.81M	189.36M
Operating Income+	244.7M	231.1M	274.48M	240.86M	267.43M	257.56M	233.99M	110.85M	48.27M	-151.59M
Operating Margin %	0.11%	0.1%	0.12%	0.09%	0.11%	0.1%	0.09%	0.05%	0.02%	-0.09%
Operating Income Growth %	-0.31%	-0.06%	0.19%	-0.12%	0.11%	-0.04%	-0.09%	-0.53%	-0.56%	-4.14%
EBITDA+	316.07M	303.5M	346.05M	323.86M	344.08M	331.56M	359.02M	183.35M	117.49M	-81.78M
EBITDA Margin %	0.14%	0.14%	0.15%	0.12%	0.14%	0.13%	0.13%	0.08%	0.06%	-0.05%
EBITDA Growth %	-0.22%	-0.04%	0.14%	-0.06%	0.06%	-0.04%	0.08%	-0.49%	-0.36%	-1.7%
D&A (Non-Cash Add-back)	71.36M	72.4M	71.56M	83M	76.65M	73.99M	125.02M	72.51M	69.22M	69.81M
EBIT	244.7M	231.1M	274.48M	311.55M	267.43M	257.56M	243.46M	102.46M	133.76M	-148.64M
Net Interest Income+	0	0	0	0	0	24K	157K	-11.49M	-25.56M	-26.41M
Interest Income	0	0	0	0	19.2M	13.12M	11.16M	10.38M	0	0
Interest Expense	0	0	0	0	19.2M	13.1M	11M	21.88M	25.56M	26.41M
Other Income/Expense	-32.74M	-18.27M	-8.92M	-21.19M	-12.25M	-1.33M	-1.53M	-21.88M	-21.69M	-23.47M
Pretax Income+	211.96M	212.84M	265.57M	219.67M	255.17M	256.23M	232.46M	88.97M	26.58M	-175.05M
Pretax Margin %	0.09%	0.1%	0.12%	0.08%	0.11%	0.1%	0.09%	0.04%	0.01%	-0.1%
Income Tax+	78.91M	69.75M	136.13M	97.78M	81.62M	64.88M	85.19M	-15.81M	17.98M	-28.46M
Effective Tax Rate %	0.63%	0.67%	0.49%	0.55%	0.68%	0.75%	0.63%	1.18%	0.32%	0.84%
Net Income+	133.05M	143.09M	129.44M	121.89M	173.55M	191.35M	147.27M	104.78M	8.6M	-146.59M
Net Margin %	0.06%	0.06%	0.06%	0.05%	0.07%	0.07%	0.05%	0.05%	0%	-0.08%
Net Income Growth %	-0.3%	0.08%	-0.1%	-0.06%	0.42%	0.1%	-0.23%	-0.29%	-0.92%	-18.06%
Net Income (Continuing)	133.05M	143.09M	129.44M	121.89M	173.55M	191.35M	147.27M	104.78M	8.6M	-146.59M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	2.25	2.55	2.36	2.16	3.10	3.63	2.86	2.07	0.17	-2.95
EPS Growth %	-0.28%	0.13%	-0.07%	-0.08%	0.44%	0.17%	-0.21%	-0.28%	-0.92%	-18.35%
EPS (Basic)	2.29	2.58	2.45	2.21	3.13	3.66	2.93	2.10	0.17	-2.95
Diluted Shares Outstanding	59.06M	56.1M	54.85M	56.48M	55.93M	52.77M	51.43M	50.52M	49.86M	49.66M
Basic Shares Outstanding	58M	55.41M	52.81M	55.17M	55.52M	52.3M	50.19M	50M	49.71M	49.66M
Dividend Payout Ratio	0.61%	0.55%	0.59%	0.66%	0.47%	0.41%	0.52%	0.74%	9.03%	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	706.39M	714.34M	777.79M	799.24M	740.17M	903.2M	872.95M	759.87M	701.87M	538.6M
Cash & Short-Term Investments	303.73M	368.13M	438.25M	398.26M	344.04M	423.9M	354.81M	278.51M	267.82M	197.99M
Cash Only	289.35M	357.25M	426.4M	386.91M	335.63M	402.68M	339.59M	264.73M	256.06M	186.88M
Short-Term Investments	14.37M	10.88M	11.85M	11.35M	8.41M	21.22M	15.22M	13.78M	11.76M	11.11M
Accounts Receivable	35.46M	31.2M	33.2M	53.28M	50.38M	63.37M	41.3M	47.36M	72.88M	50.78M
Days Sales Outstanding	5.76	5.16	5.32	7.26	7.6	8.96	5.59	7.77	13.51	10.7
Inventory	265.26M	249.94M	253.45M	295.82M	275.89M	314.37M	399.93M	346.18M	279.98M	190.24M
Days Inventory Outstanding	197.79	182.29	184.26	170.27	173.2	174.37	216.19	200.28	167.02	126.2
Other Current Assets	29.23M	24.04M	18.4M	22.51M	24.51M	25.27M	32.43M	39.33M	37.1M	51.39M
Total Non-Current Assets+	799.45M	759.71M	812.08M	895.21M	1.03B	1.05B	1.03B	1.06B	1.1B	930.32M
Property, Plant & Equipment	454.54M	444.73M	464.59M	464.54M	644.82M	653.45M	598.25M	571.67M	523.07M	466.91M
Fixed Asset Turnover	4.94x	4.96x	4.91x	5.77x	3.75x	3.95x	4.51x	3.89x	3.76x	3.71x
Goodwill	112.45M	114.95M	114.95M	196.57M	196.57M	202.98M	206.43M	206.43M	230.77M	83.63M
Intangible Assets	67.01M	63.55M	67.65M	89.99M	80.32M	89.53M	76.99M	66.7M	105.31M	74.28M
Long-Term Investments	-40.37M	-35.75M	-33.78M	-37.33M	0	11.34M	35.87M	39.49M	40.11M	39.59M
Other Non-Current Assets	165.46M	136.47M	164.9M	144.11M	76.34M	61.16M	89.51M	87.03M	99.81M	91.67M
Total Assets+	1.51B	1.47B	1.59B	1.69B	1.77B	1.96B	1.91B	1.82B	1.81B	1.47B
Asset Turnover	1.49x	1.50x	1.43x	1.58x	1.37x	1.32x	1.41x	1.22x	1.09x	1.18x
Asset Growth %	-0.07%	-0.02%	0.08%	0.07%	0.04%	0.11%	-0.03%	-0.04%	-0.01%	-0.19%
Total Current Liabilities+	407.6M	399.01M	447.37M	439.65M	356.76M	542.86M	529.69M	359.24M	328.87M	296.61M
Accounts Payable	28.83M	41.26M	50.34M	47.62M	38.98M	66.17M	49.99M	53.96M	43.51M	34.88M
Days Payables Outstanding	21.5	30.09	36.6	27.41	24.47	36.71	27.02	31.22	25.95	23.14
Short-Term Debt	67.85M	82.73M	77.84M	69.45M	27.5M	30M	107.5M	25M	25M	30M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	279.88M	109.96M	103.73M	99.63M	3.9M	137.97M	3.51M	3.36M	89.64M	23.89M
Current Ratio	1.73x	1.79x	1.74x	1.82x	2.07x	1.66x	1.65x	2.12x	2.13x	1.82x
Quick Ratio	1.08x	1.16x	1.17x	1.15x	1.30x	1.08x	0.89x	1.15x	1.28x	1.17x
Cash Conversion Cycle	182.05	157.35	152.98	150.12	156.32	146.63	194.76	176.82	154.58	113.76
Total Non-Current Liabilities+	272.63M	410.96M	437.91M	472.92M	536.96M	519.95M	464.01M	564.43M	655.62M	520.85M
Long-Term Debt	181.75M	334.17M	310.79M	361.01M	334.46M	305.39M	268.78M	377.47M	478.04M	363.61M
Capital Lease Obligations	0	0	0	9.33M	105.7M	120M	94.08M	88.68M	80.39M	66.69M
Deferred Tax Liabilities	16.18M	643K	36.72M	32.62M	27.86M	23.36M	24.16M	35.97M	522K	39.87M
Other Non-Current Liabilities	90.88M	76.8M	127.12M	102.58M	68.93M	71.2M	77M	62.31M	96.67M	50.68M
Total Liabilities	680.22M	809.98M	885.28M	912.58M	893.72M	1.06B	993.71M	923.67M	984.5M	817.46M
Total Debt+	249.59M	416.89M	388.63M	430.46M	507.01M	500.38M	503.79M	520.52M	607.33M	478.23M
Net Debt	-39.76M	59.65M	-37.77M	43.55M	171.38M	97.69M	164.19M	255.8M	351.27M	291.34M
Debt / Equity	0.30x	0.63x	0.55x	0.55x	0.58x	0.56x	0.55x	0.58x	0.74x	0.73x
Debt / EBITDA	0.79x	1.37x	1.12x	1.33x	1.47x	1.51x	1.40x	2.84x	5.17x	-
Net Debt / EBITDA	-0.13x	0.20x	-0.11x	0.13x	0.50x	0.29x	0.46x	1.40x	2.99x	-
Interest Coverage	-	-	-	-	13.93x	19.66x	21.27x	5.07x	1.89x	-5.74x
Total Equity+	825.62M	664.07M	704.6M	781.87M	875.29M	894.27M	912.77M	897.3M	821.97M	651.46M
Equity Growth %	-0.12%	-0.2%	0.06%	0.11%	0.12%	0.02%	0.02%	-0.02%	-0.08%	-0.21%
Book Value per Share	13.98	11.84	12.85	13.84	15.65	16.95	17.75	17.76	16.49	13.12
Total Shareholders' Equity	825.62M	664.07M	704.6M	781.87M	875.29M	894.27M	912.77M	897.3M	821.97M	651.46M
Common Stock	91K	91K	91K	91K	91K	91K	91K	91K	91K	91K
Retained Earnings	1.49B	1.56B	1.61B	1.64B	1.73B	1.84B	1.91B	1.94B	1.87B	1.71B
Treasury Stock	-1.02B	-1.25B	-1.3B	-1.33B	-1.32B	-1.46B	-1.53B	-1.57B	-1.57B	-1.56B
Accumulated OCI	-71.27M	-84.12M	-66.32M	-79.93M	-85.29M	-64.77M	-73.9M	-86.51M	-100.01M	-124.76M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	322.11M	275.26M	302.56M	202.74M	177.93M	379.14M	141.58M	108.06M	118.64M	111.74M
Operating CF Margin %	0.14%	0.12%	0.13%	0.08%	0.07%	0.15%	0.05%	0.05%	0.06%	0.06%
Operating CF Growth %	6.7%	-0.15%	0.1%	-0.33%	-0.12%	1.13%	-0.63%	-0.24%	0.1%	-0.06%
Net Income	133.05M	143.09M	129.44M	121.89M	173.55M	191.35M	147.27M	104.78M	8.6M	-146.59M
Depreciation & Amortization	71.36M	72.4M	71.56M	83M	76.65M	73.99M	76.32M	72.51M	70.92M	69.81M
Stock-Based Compensation	7.4M	8.89M	19.31M	26.61M	9.91M	24.06M	23.19M	12.37M	15.65M	14.82M
Deferred Taxes	17.36M	-17.65M	39.21M	-14.93M	1.97M	-11.91M	5.82M	-51.63M	-18.09M	-55.48M
Other Non-Cash Items	27.23M	40.22M	-4.06M	58.05M	48.29M	49.09M	82.6M	62.71M	123.25M	257.51M
Working Capital Changes	65.7M	28.32M	47.09M	-71.88M	-132.44M	52.56M	-193.62M	-92.67M	-81.68M	-28.34M
Change in Receivables	-2.25M	3.36M	-103K	-10.45M	2.75M	-11.21M	20.22M	-11.45M	-22.68M	-7.76M
Change in Inventory	59.65M	9.8M	7.54M	-33.37M	18.45M	-31.14M	-95.32M	40.31M	-13.22M	30.32M
Change in Payables	-4.3M	13.44M	6.83M	-9.16M	-7.18M	24.84M	-13.28M	9.26M	-10.08M	-7.29M
Cash from Investing+	-60.85M	-57.86M	-91.96M	-108.76M	-71.41M	-79.43M	-88.73M	-67.08M	-134.5M	-37.96M
Capital Expenditures	-56.62M	-50.22M	-60.16M	-70.37M	-66.07M	-63.82M	-68.61M	-59.06M	-58.49M	-41.58M
CapEx % of Revenue	0.03%	0.02%	0.03%	0.03%	0.03%	0.02%	0.03%	0.03%	0.03%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-4.22M	1.05M	-63K	116K	0	0	0	-8.02M	0	0
Cash from Financing+	-235.92M	-134.71M	-159.57M	-116.71M	-154.79M	-245.17M	-104.7M	-99.5M	10.73M	-133.18M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-81.19M	-78.44M	-76.06M	-80.58M	-82.19M	-78.39M	-76.27M	-77.02M	-77.62M	-11.93M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	8.65M	13.36M	24.44M	3.53M	-2.33M	5.76M	13.86M	21.98M	4.56M	-6.3M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	265.49M	225.04M	242.4M	132.37M	111.86M	315.32M	72.97M	49.01M	60.15M	70.16M
FCF Margin %	0.12%	0.1%	0.11%	0.05%	0.05%	0.12%	0.03%	0.02%	0.03%	0.04%
FCF Growth %	2.68%	-0.15%	0.08%	-0.45%	-0.15%	1.82%	-0.77%	-0.33%	0.23%	0.17%
FCF per Share	4.50	4.01	4.42	2.34	2.00	5.98	1.42	0.97	1.21	1.41
FCF Conversion (FCF/Net Income)	2.42x	1.92x	2.34x	1.66x	1.03x	1.98x	0.96x	1.03x	13.80x	-0.76x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	15.05%	19.21%	18.91%	16.4%	20.95%	21.63%	16.3%	11.58%	1%	-19.9%
Return on Invested Capital (ROIC)	21.75%	22.96%	29.61%	24.21%	21.43%	18.95%	16.96%	7.46%	3.11%	-10.75%
Gross Margin	78.22%	77.33%	77.97%	76.33%	75.98%	74.51%	74.95%	71.65%	68.93%	68.23%
Net Margin	5.92%	6.48%	5.68%	4.55%	7.17%	7.41%	5.46%	4.71%	0.44%	-8.46%
Debt / Equity	0.30x	0.63x	0.55x	0.55x	0.58x	0.56x	0.55x	0.58x	0.74x	0.73x
Interest Coverage	-	-	-	-	13.93x	19.66x	21.27x	5.07x	1.89x	-5.74x
FCF Conversion	2.42x	1.92x	2.34x	1.66x	1.03x	1.98x	0.96x	1.03x	13.80x	-0.76x
Revenue Growth	-12.55%	-1.75%	3.23%	17.55%	-9.65%	6.67%	4.41%	-17.44%	-11.53%	-12.04%

Revenue by Segment

	2014	2015	2017	2018	2019	2020	2021	2022	2023	2024
Nu Skin	1.56B	1.36B	1.46B	1.66B	2.3B	2.43B	2.52B	2.07B	1.75B	1.45B
Nu Skin Growth	-	-12.74%	6.81%	13.96%	38.48%	5.80%	3.67%	-17.80%	-15.43%	-17.52%
Manufacturing	-	-	-	-	121.92M	149.34M	172.12M	149.46M	181.4M	201.43M
Manufacturing Growth	-	-	-	-	-	22.49%	15.25%	-13.17%	21.37%	11.04%
Rhyz Other	-	-	-	-	-	-	437K	3.83M	35.21M	85.19M
Rhyz Other Growth	-	-	-	-	-	-	-	776.43%	819.43%	141.92%
Grow Tech	-	-	-	-	137K	903K	-	-	-	-
Grow Tech Growth	-	-	-	-	-	559.12%	-	-	-	-
Pharmanex	1B	877.92M	817.23M	921.33M	-	-	-	-	-	-
Pharmanex Growth	-	-12.23%	-6.91%	12.74%	-	-	-	-	-	-
Other Product Lines	6.62M	5.58M	5.48M	97.94M	-	-	-	-	-	-
Other Product Lines Growth	-	-15.66%	-1.81%	1686.30%	-	-	-	-	-	-

Revenue by Geography

	2014	2015	2017	2018	2019	2020	2021	2022	2023	2024
Americas	-	-	-	-	-	-	547.75M	508.54M	398.22M	322.52M
Americas Growth	-	-	-	-	-	-	-	-7.16%	-21.69%	-19.01%
Southeast Asia/Pacific	-	-	-	-	-	-	336.65M	344.41M	267.21M	244.85M
Southeast Asia/Pacific Growth	-	-	-	-	-	-	-	2.31%	-22.42%	-8.37%
Mainland China	-	-	-	-	-	625.54M	568.77M	360.39M	298.08M	235.24M
Mainland China Growth	-	-	-	-	-	-	-9.07%	-36.64%	-17.29%	-21.08%
Japan	-	-	-	-	-	273.68M	266.22M	224.9M	207.83M	181.56M
Japan Growth	-	-	-	-	-	-	-2.73%	-15.52%	-7.59%	-12.64%
Europe and Africa	-	-	-	-	-	-	-	-	192.35M	164.16M
Europe and Africa Growth	-	-	-	-	-	-	-	-	-	-14.65%
EMEA	-	-	-	-	-	230.25M	283.2M	204.28M	-	-
EMEA Growth	-	-	-	-	-	-	23.00%	-27.87%	-	-
Americas/ Pacific	-	-	-	-	-	511.94M	-	-	-	-
Americas/ Pacific Growth	-	-	-	-	-	-	-	-	-	-
Southeast Asia	-	-	-	-	-	302.71M	-	-	-	-
Southeast Asia Growth	-	-	-	-	-	-	-	-	-	-
Mainland China	-	-	716.99M	886.47M	722.53M	-	-	-	-	-
Mainland China Growth	-	-	-	23.64%	-18.49%	-	-	-	-	-
Americas/Pacific	-	-	-	385.03M	349.08M	-	-	-	-	-
Americas/Pacific Growth	-	-	-	-	-9.34%	-	-	-	-	-
South Korea	-	-	361.69M	373.36M	329.98M	-	-	-	-	-
South Korea Growth	-	-	-	3.23%	-11.62%	-	-	-	-	-
Southeast Asia	-	-	-	316.89M	301.62M	-	-	-	-	-
Southeast Asia Growth	-	-	-	-	-4.82%	-	-	-	-	-
Japan	-	-	256.08M	254.94M	260.04M	-	-	-	-	-
Japan Growth	-	-	-	-0.45%	2.00%	-	-	-	-	-
EMEA	180.57M	-	160.28M	182.39M	167.16M	-	-	-	-	-
EMEA Growth	-	-	-	13.80%	-8.35%	-	-	-	-	-
Hong Kong/Taiwan	-	-	166.7M	185.89M	166.34M	-	-	-	-	-
Hong Kong/Taiwan Growth	-	-	-	11.52%	-10.52%	-	-	-	-	-
Other	-	-	-	94.03M	-	-	-	-	-	-
Other Growth	-	-	-	-	-	-	-	-	-	-
Americas	329.03M	329.67M	317.38M	-	-	-	-	-	-	-
Americas Growth	-	0.19%	-3.73%	-	-	-	-	-	-	-
South Asia Pacific	328.39M	321.97M	299.98M	-	-	-	-	-	-	-
South Asia Pacific Growth	-	-1.95%	-6.83%	-	-	-	-	-	-	-
China	948.52M	771.67M	-	-	-	-	-	-	-	-
China Growth	-	-18.65%	-	-	-	-	-	-	-	-
North Asia	782.99M	686.55M	-	-	-	-	-	-	-	-
North Asia Growth	-	-12.32%	-	-	-	-	-	-	-	-
Europe	-	137.19M	-	-	-	-	-	-	-	-
Europe Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Nu Skin Enterprises, Inc. (NUS) reported $1.56B in revenue for fiscal year 2024. This represents a 11% decrease from $1.74B in 2011.

Nu Skin Enterprises, Inc. (NUS) saw revenue decline by 12.0% over the past year.

Yes, Nu Skin Enterprises, Inc. (NUS) is profitable, generating $109.6M in net income for fiscal year 2024 (-8.5% net margin).

Dividend & Returns

Yes, Nu Skin Enterprises, Inc. (NUS) pays a dividend with a yield of 2.12%. This makes it attractive for income-focused investors.

Nu Skin Enterprises, Inc. (NUS) has a return on equity (ROE) of -19.9%. Negative ROE indicates the company is unprofitable.

Nu Skin Enterprises, Inc. (NUS) generated $53.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.